Research Agency Funding

Funding opportunities and resources regarding COVID-19. Contact for any foundation or corporate opportunities. For all other inquiries contact

Sponsors and program information
Sponsor Program Title Identifier Description Deadline Funding Area
NIH Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding Current and comprehensive coronavirus updates
NIH NIH Funding Opportunities Specific to COVID-19 Comprehensive NIH Funding Opportunities.
NIH Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2) NOT-OD-21-065 NIH plans to publish a Research Opportunity (RO) as part of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative to solicit research on COVID-19 diagnostic testing approaches to safely return children and staff to the in-person school setting in underserved and vulnerable communities. The RO will consist of two phases: 1) a targeted solicitation to rapidly accelerate ongoing research already in place in the school setting; 2) an open solicitation to start new cohorts or approaches to gain data related to safe return. TBD Diagnostic Testing in Schools
NIH NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) PAR-20-072 The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of healthy immune system development and function across the lifespan; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. January 11, 2022; June 10, 2022 Vaccine Development
NIH Emergency Awards: Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern (U19 Clinical Trial Not Allowed)
To support comprehensive multidisciplinary research Centers focused on innovative antiviral drug development targeting coronaviruses (CoVs), emphasizing SARS-CoV-2, and one or more select RNA viruses with pandemic potential. 10/22/21 Antiviral Drug Discovery
NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI) NOT-AI-21-008 The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. 1/8/23 Immunology
NIH Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), PA-20-135 PA-20-135 See "Components of Participating Organization" for participating IC's and "Related Notices" Notice of Special Interest (NOSI) announcements for specific research/program interests. Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA. See IC Emergency Notice of Special Interest (NOSI) many
NIH Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional), PA-18-935
PA-18-935 See "Components of Participating Organization" for participating IC's and "Related Notices" Notice of Special Interest (NOSI) announcements for specific research/program interests. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. See IC Emergency Notice of Special Interest (NOSI) many
NIH Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-20-272
See "Components of Participating Organization" for participating IC's and "Related Notices" Notice of Special Interest (NOSI) announcements for specific research/program interests. You must have an existing award from relevant IC. See IC website many
NIH NIEHS, Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed), RFA-ES-19-011 RFA-ES-19-011 The goal of the program is to characterize initial exposures, collect human biological samples, or collect human health and exposure data in order to provide critical information to understand exposure-health outcome relationships, with the goal of providing data that will facilitate timely action to protect public health." The 2-year project period may not exceed $275,000. Proposals accepted monthly on the first of the month. monthly through Oct. 2022
Environmental Health
NIH Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) PA-20-172 To invite robust investigative and collaborative research focused on understanding the long-term effects of disasters on health disparity populations and the health care systems that serve them, including the influence of risk factors or vulnerabilities of both the systems and the communities preceding the event(s). Standard dates through Sept. 2023
Healthcare Systems & Disasters
NIH POCTRN Fast-Track Program for COVID-19 Test Development and Distribution PAR-17-453 Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing. NIBIB is urgently soliciting proposals to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). continued until further notice
Rapid Testing
NIH Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth NOT-HD-21-026 It is anticipated that research stemming from this NOSI will help to provide greater recognition of the need for better resources and support for vulnerable children. More touchpoints for communication, identification and screening for risks of child trauma, and injury will help inform processes for screening, identification, treatment and care in new and emerging disaster related contexts in the future. Varies by opportunity
Screening, ID, treatment and care for child abuse
NIH Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders NOT-DC-20-008 There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Varies by opportunity Healthcare
NIH Notice of Special Interest (NOSI) – Research on Rehabilitation Needs Associated with the COVID-19 Pandemic NOT-HD-20-031 To encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: (1) Encourage research to address the rehabilitation needs of survivors of COVID-19. (2) Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions. (3) Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities 2/15/21 through 5/8/23 Rehabilitation and Mitigation
NIH Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research NOT-AI-21-071
Use mouse lines from the Collaborative Cross (CC) and recombinant inbred intercrosses of CC lines (CC-RIX) to more faithfully reproduce human immune responses and to advance understanding of the host genetics involved in immune regulation and function. Screen CC mouse lines to identify and characterize lines suitable for specific studies and disease models within the mission of NIAID (e.g., fundamental immunology, immune-mediated diseases, infectious diseases).
This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 7, 2024 Immunoregulatory and Infectious Disease
NIH Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed) RFA-AI-21-021 For the enhancement and/or sustainment of high-value data science research software to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge across the immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. February 17, 2022, July 01, 2022
Data Management
NIH Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed) RFA-AI-21-020 To solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. February 17, 2022, July 01, 2022
Data Dissemination
NIH Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed) RFA-AI-21-035 To support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. February 17, 2022, July 01, 2022 Tool development
NIH National COVID Cohort Collaborative: N3C Cohort Exploration Dashboard The NCATS National COVID Cohort Collaborative (N3C) Data Enclave represents one of the largest, most secure clinical data resources for accelerating research on COVID-19. It also includes a powerful analytics platform and tool set for online discovery, visualization and collaboration. The data set and analytics capabilities will grow over time. Resource
HHS BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement BAA-20-100-SOL-0002 Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform, Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease, Nonclinical model development and screening for SARS-CoV-2 virus, Alternate vaccine delivery/administration and adjuvants, and Advanced manufacturing technologies. Rolling Diagnostics
NSF Coronavirus Information Current and comprehensive coronavirus updates. DCL NSF 20-052 has been archived. NSF encourages PIs to explore existing funding opportunities across NSF and to contact the cognizant NSF Program Officers for relevant programs; NSF remains open to inquiries concerning COVID-19 research in response to existing programs.
DHS Frequently Asked Questions for DOD Research Proposers and Awardees Impacted by the Novel Coronavirus (COVID-19) Therapeutics
DOE Office of Science Director Dear Colleagues Letter Soliciting "scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure.
CDC US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings RFA-IP-22-004 The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended. Estimated 2/1/22 Infectious disease prevention
CDC Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19 RFA-IP-22-003 To evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. 11/1/21 Vaccine effectiveness
FDA Innovation Grant: COVID-19 and Health Equity (R01) Clinical Trials Optional FOR-FD-22-001 COVID research that will strengthen and advance research in minority health and healthy equity, increase understanding of health disparities, and provide future direction for research that will contribute to regulatory decision making. 3/31/22 Health Interventions
University of California UC MEXUS SUPPLEMENTAL COVID-19 FUNDING OPPORTUNITY UC MEXUS ( supplemental funding opportunity for UC faculty undertaking research on COVID-19 who want to engage with Mexico. Bi-national collaboration
CIRM Special Call for COVID-19 Projects COVID-19 To support promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need. CIRM has established an open call for proposals and will accept applications on a bi-monthly basis. Rolling deadline, every 2 months Treatments
Gates Foundation COVID-19 Therapeutics Accelerator Announcement Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19. Therapeutics
Ford Foundation + many Five Foundations Commit $1.7+ Billion to Nonprofit Organizations in Wake of Pandemic Doris Duke Charitable Foundation, Ford Foundation, W.K. Kellogg Foundation, the John D. & Catherine T. MacArthur Foundation, and the Andrew W. Mellon Foundation announced a joint commitment to increase their payouts to nonprofit organizations with more than $1.7 billion within the next three years to help stabilize and sustain a nonprofit sector facing devastating economic effects due to the global pandemic and the epidemic of social injustice.
Ford Foundation + many Families and Workers Fund The Families and Workers Fund is an opportunity to not just recover and return to business-as-usual, but to also build a stronger, more equitable society where there is greater economic security, opportunity, and work with dignity for all. Target areas include Direct Relief and Centering Vulnerable Workers and Families in the Economic Response to COVID-19 See funder for updates Social Sciences, Humanities, Economics
Bloomberg Philanthropies Coronavirus Global Response Initiative & Local Response Initiative This global initiative will support immediate action to prevent or slow the spread of COVID-19 in vulnerable low- and middle-income countries Health Interventions
The COVID-19 High Performance Computing Consortium COVID-19 High Performance Computing (HPC) Consortium Sponsored by the White House Office of Science and Technology to aggregate computational resources for "extensive research in areas like bioinformatics, epidemiology, and molecular modeling to understand the threat we’re facing and form strategies to address it. Tech interventions
Pfizer PFIZER’S COMPETITIVE GRANTS PROGRAM Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. many many
Amazon Web Services AWS Diagnostic Development Initiative (DDI) AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies. 12/31/21 Resource
Ginko Bioworks Ginkgo Bioworks Partnerships Free platform access, connections to sources of funding, and R&D information sharing. Resource
23andMe 23andMe Research Innovation Collaborations Program The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort. rolling Resource
Other NIST Tools for Searching the Coronavirus Dataset New resources to allow researchers to get the most from the COVID-19 Open Research Dataset (CORD-19), a collection of scientific literature about coronaviruses containing tens of thousands of items. Resource
Other ICODA Tools For Researchers The International COVID-19 Data Alliance (ICODA) is a “Workbench” that allows researchers to discover, access and analyse global multi-dimensional datasets The platform will consolidate data and metadata from federated repositories to allow teams to work collectively on a focused research question. Data access and use is subject to rigorous data governance processes, based on the five safes framework. Resource
Other Meta A research discovery tool that uses machine learning to help researchers keep pace with discoveries through targeted feeds, maps both published papers and preprints — providing a single site to see them in one place. Resource
Other COVID-19 Open Research Dataset (CORD-19) Prepare and distribute a set of research literature about COVID-19, SARS-CoV-2, and the coronavirus group. Resource
Other Rapid Access for COVID-19 Research Department of Energy Basic Energy Sciences advanced neutron sources will provide remote rapid access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapies. Facilities that will be made available at the Spallation Neutron Source (SNS) and High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory (ORNL), include neutron macromolecular crystallography, small-angle scattering, reflectometry, spectroscopy and imaging beamlines. Resource